252 related articles for article (PubMed ID: 26313693)
1. Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis.
Boyle M; Ting A; Cury DB; Nanda K; Cheifetz AS; Moss A
Inflamm Bowel Dis; 2015 Dec; 21(12):2873-8. PubMed ID: 26313693
[TBL] [Abstract][Full Text] [Related]
2. Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD.
Moss AC; Lillis Y; Edwards George JB; Choudhry NK; Berg AH; Cheifetz AS; Horowitz G; Leffler DA
Am J Gastroenterol; 2014 Dec; 109(12):1850-5. PubMed ID: 24913040
[TBL] [Abstract][Full Text] [Related]
3. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis.
Yen L; Wu J; Hodgkins PL; Cohen RD; Nichol MB
J Manag Care Pharm; 2012; 18(9):701-12. PubMed ID: 23206213
[TBL] [Abstract][Full Text] [Related]
4. Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis.
Kane S; Katz S; Jamal MM; Safdi M; Dolin B; Solomon D; Palmen M; Barrett K
Inflamm Bowel Dis; 2012 Jun; 18(6):1026-33. PubMed ID: 21837775
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis.
Kane SV; Cohen RD; Aikens JE; Hanauer SB
Am J Gastroenterol; 2001 Oct; 96(10):2929-33. PubMed ID: 11693328
[TBL] [Abstract][Full Text] [Related]
6. Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose.
Khan N; Abbas AM; Koleva YN; Bazzano LA
Inflamm Bowel Dis; 2013 May; 19(6):1123-9. PubMed ID: 23514878
[TBL] [Abstract][Full Text] [Related]
7. A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study.
Gifford AE; Berg AH; Lahiff C; Cheifetz AS; Horowitz G; Moss AC
Am J Gastroenterol; 2013 Feb; 108(2):249-55. PubMed ID: 23295279
[TBL] [Abstract][Full Text] [Related]
8. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis.
Kane S; Huo D; Aikens J; Hanauer S
Am J Med; 2003 Jan; 114(1):39-43. PubMed ID: 12543288
[TBL] [Abstract][Full Text] [Related]
9. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis.
Kane S; Huo D; Magnanti K
Clin Gastroenterol Hepatol; 2003 May; 1(3):170-3. PubMed ID: 15017487
[TBL] [Abstract][Full Text] [Related]
10. Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis.
Li W; Zhang ZM; Jiang XL
Colorectal Dis; 2016 Jul; 18(7):O214-23. PubMed ID: 27214762
[TBL] [Abstract][Full Text] [Related]
11. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis.
Mitra D; Hodgkins P; Yen L; Davis KL; Cohen RD
BMC Gastroenterol; 2012 Sep; 12():132. PubMed ID: 23006789
[TBL] [Abstract][Full Text] [Related]
12. Barriers to mesalamine adherence in patients with inflammatory bowel disease: a qualitative analysis.
Devlen J; Beusterien K; Yen L; Ahmed A; Cheifetz AS; Moss AC
J Manag Care Spec Pharm; 2014 Mar; 20(3):309-14. PubMed ID: 24564811
[TBL] [Abstract][Full Text] [Related]
13. Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis--a prospective study.
Moss AC; Chaudhary N; Tukey M; Junior J; Cury D; Falchuk KR; Cheifetz AS
J Crohns Colitis; 2010 Jun; 4(2):171-5. PubMed ID: 21122501
[TBL] [Abstract][Full Text] [Related]
14. Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis.
Gillespie D; Hood K; Farewell D; Stenson R; Probert C; Hawthorne AB
Inflamm Bowel Dis; 2014 Jan; 20(1):82-91. PubMed ID: 24284414
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis.
Andus T; Kocjan A; Müser M; Baranovsky A; Mikhailova TL; Zvyagintseva TD; Dorofeyev AE; Lozynskyy YS; Cascorbi I; Stolte M; Vieth M; Dilger K; Mohrbacher R; Greinwald R;
Inflamm Bowel Dis; 2010 Nov; 16(11):1947-56. PubMed ID: 20310020
[TBL] [Abstract][Full Text] [Related]
16. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
17. Systematic review: adherence issues in the treatment of ulcerative colitis.
Kane SV
Aliment Pharmacol Ther; 2006 Mar; 23(5):577-85. PubMed ID: 16480396
[TBL] [Abstract][Full Text] [Related]
18. Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study.
Keil R; Wasserbauer M; Zádorová Z; Kojecký V; Hlava Š; Št'ovíček J; Chudý J; Roznětinská M; Drábek J; Kubišová N; Lochmannová J
Scand J Gastroenterol; 2018 Apr; 53(4):459-465. PubMed ID: 29560753
[TBL] [Abstract][Full Text] [Related]
19. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database.
Lachaine J; Yen L; Beauchemin C; Hodgkins P
BMC Gastroenterol; 2013 Jan; 13():23. PubMed ID: 23363459
[TBL] [Abstract][Full Text] [Related]
20. Telephone nurse counseling for medication adherence in ulcerative colitis: a preliminary study.
Cook PF; Emiliozzi S; El-Hajj D; McCabe MM
Patient Educ Couns; 2010 Nov; 81(2):182-6. PubMed ID: 20079598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
